LOADING
Comparing Eli Lilly and Company (LLY) and JPMorgan Chase (JPM) across the Health Care and Financials sectors. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | LLY | JPM |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $1.12T | $934.6B |
| P/E Ratio | 41.9 | 15.1 |
| Forward P/E | 34.3 | 14.8 |
| PEG Ratio | 1.56 | 1.72 |
| EPS | $30.00 | $23.34 |
| Revenue Growth (YoY) | 47.7% | 30.4% |
| Profit Margin | 33.5% | 34.9% |
| Return on Equity | 102.3% | 17.8% |
| Dividend Yield | 0.52% | 1.71% |
| Beta | 0.51 | 0.98 |
| 52-Week High | $1,292.65 | $366.50 |
| 52-Week Low | $689.88 | $276.44 |
| Volume | -- | -- |
Eli Lilly and Company is the larger company by market capitalization. JPMorgan Chase trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. JPMorgan Chase offers a higher dividend yield for income investors. JPMorgan Chase has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.